Accelerator · 1 deal
Every published round MedTech Innovator took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Biorithm | Accelerator | 12 Jul 2021 | - | Lead | Wholesale Investor (Mon 12 Jul 2021), Wholesale Investor (Wed 18 Nov 2020) |
Everyone MedTech Innovator has named to a program in published coverage. A place in a program is not a raise: the cheque is the figure recorded with the place, which is the program's standard terms where we hold them, and a blank is one we don't.
Companies MedTech Innovator has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Biorithm | 12 Jul 2021, Accelerator | 1 | 1 |
Fund closes reported for MedTech Innovator, as distinct from the investments it has made.
Companies MedTech Innovator has backed that another company then bought. An exit for the holding, not a deal MedTech Innovator did.
| Name | Role | Sources |
|---|---|---|
| Paul Grand | CEO | Startup Daily |
Stories naming MedTech Innovator. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Maternal health medtech Biorithm, spun out of a Singapore university, has joined the 2021 MedTech Innovator Asia Pacific accelerator cohort, gaining mentorship, investor exposure, and a chance at US$300,000 in prizes.
Profile of digital health company Naluri, covering its chronic disease care platform, a stated US$4 million Series A at US$23 million pre-money, earlier Malaysian grants, accelerator programs and planned regional expansion.
Perth medtech OncoRes Medical joins the MedTech Innovator accelerator as the sole Australian company among 25 international startups, having earlier raised $6 million from the Medical Research Commercialisation Fund.